Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
Please stay tuned for additional content to this program available for credit. The maximum amount of credits available for the entire activity is 1.0.
Create your
podcast in
minutes
It is Free